California Proposition 38, set for the November 2026 ballot, would authorize $8.4 billion in general obligation bonds for immunology and immunotherapy research, with half directed to a designated University of California-affiliated institute and the balance awarded via competitive grants, at least $4.2 billion of which must target cancer, heart disease, and Alzheimer’s. Trader sentiment favoring rejection at 55% reflects concerns over the measure’s eligibility criteria, which critics note appear structured to channel substantial funds to one specific nonprofit backed by its billionaire co-founder, alongside broader worries about long-term General Fund repayment obligations and fragmented state research priorities. Recent analyses from the Legislative Analyst’s Office and opinion pieces have highlighted these design elements and debt implications, contributing to the current market positioning ahead of the vote.
สรุปจาก AI ทดลองที่อ้างอิงข้อมูลจาก Polymarket ไม่ใช่คำแนะนำในการเทรดและไม่มีผลต่อการตัดสินตลาดนี้ · อัปเดตแล้วCalifornia Immunology Research Bond Proposition
California Immunology Research Bond Proposition
54% โอกาส
ใหม่
ใหม่
Nov 3, 2026
54% โอกาส
ใหม่
ใหม่
Nov 3, 2026
Proposition 38 is a California ballot measure currently scheduled for voting on November 3, 2026. It would allow the state to borrow $8.4 billion in debt to research immune system-based technologies for treating conditions including cancer, heart disease and Alzheimer’s.
This market will resolve to “Yes” if the specified ballot measure is approved by a majority of voters at the California statewide general election currently scheduled for November 3, 2026. Otherwise, this market will resolve to “No.”
If voting on the specified ballot measure does not occur, or the results thereof are not known definitively, by March 31, 2027, this market will resolve to “No”.
This market will resolve based on a consensus of credible reporting. If there is ambiguity, this market will resolve solely based on official information from the State of California, including the California Secretary of State (https://www.sos.ca.gov/).California Proposition 38, set for the November 2026 ballot, would authorize $8.4 billion in general obligation bonds for immunology and immunotherapy research, with half directed to a designated University of California-affiliated institute and the balance awarded via competitive grants, at least $4.2 billion of which must target cancer, heart disease, and Alzheimer’s. Trader sentiment favoring rejection at 55% reflects concerns over the measure’s eligibility criteria, which critics note appear structured to channel substantial funds to one specific nonprofit backed by its billionaire co-founder, alongside broader worries about long-term General Fund repayment obligations and fragmented state research priorities. Recent analyses from the Legislative Analyst’s Office and opinion pieces have highlighted these design elements and debt implications, contributing to the current market positioning ahead of the vote.
Proposition 38 is a California ballot measure currently scheduled for voting on November 3, 2026. It would allow the state to borrow $8.4 billion in debt to research immune system-based technologies for treating conditions including cancer, heart disease and Alzheimer’s.
This market will resolve to “Yes” if the specified ballot measure is approved by a majority of voters at the California statewide general election currently scheduled for November 3, 2026. Otherwise, this market will resolve to “No.”
If voting on the specified ballot measure does not occur, or the results thereof are not known definitively, by March 31, 2027, this market will resolve to “No”.
This market will resolve based on a consensus of credible reporting. If there is ambiguity, this market will resolve solely based on official information from the State of California, including the California Secretary of State (https://www.sos.ca.gov/).
This market will resolve to “Yes” if the specified ballot measure is approved by a majority of voters at the California statewide general election currently scheduled for November 3, 2026. Otherwise, this market will resolve to “No.”
If voting on the specified ballot measure does not occur, or the results thereof are not known definitively, by March 31, 2027, this market will resolve to “No”.
This market will resolve based on a consensus of credible reporting. If there is ambiguity, this market will resolve solely based on official information from the State of California, including the California Secretary of State (https://www.sos.ca.gov/).
ตลาดเปิดเมื่อ: Jul 1, 2026, 6:33 PM ET
ปริมาณการซื้อขาย
$2,851วันสิ้นสุด
Nov 3, 2026ตลาดเปิดเมื่อ
Jul 1, 2026, 6:33 PM ETResolver
0x65070BE91...Proposition 38 is a California ballot measure currently scheduled for voting on November 3, 2026. It would allow the state to borrow $8.4 billion in debt to research immune system-based technologies for treating conditions including cancer, heart disease and Alzheimer’s.
This market will resolve to “Yes” if the specified ballot measure is approved by a majority of voters at the California statewide general election currently scheduled for November 3, 2026. Otherwise, this market will resolve to “No.”
If voting on the specified ballot measure does not occur, or the results thereof are not known definitively, by March 31, 2027, this market will resolve to “No”.
This market will resolve based on a consensus of credible reporting. If there is ambiguity, this market will resolve solely based on official information from the State of California, including the California Secretary of State (https://www.sos.ca.gov/).California Proposition 38, set for the November 2026 ballot, would authorize $8.4 billion in general obligation bonds for immunology and immunotherapy research, with half directed to a designated University of California-affiliated institute and the balance awarded via competitive grants, at least $4.2 billion of which must target cancer, heart disease, and Alzheimer’s. Trader sentiment favoring rejection at 55% reflects concerns over the measure’s eligibility criteria, which critics note appear structured to channel substantial funds to one specific nonprofit backed by its billionaire co-founder, alongside broader worries about long-term General Fund repayment obligations and fragmented state research priorities. Recent analyses from the Legislative Analyst’s Office and opinion pieces have highlighted these design elements and debt implications, contributing to the current market positioning ahead of the vote.
Proposition 38 is a California ballot measure currently scheduled for voting on November 3, 2026. It would allow the state to borrow $8.4 billion in debt to research immune system-based technologies for treating conditions including cancer, heart disease and Alzheimer’s.
This market will resolve to “Yes” if the specified ballot measure is approved by a majority of voters at the California statewide general election currently scheduled for November 3, 2026. Otherwise, this market will resolve to “No.”
If voting on the specified ballot measure does not occur, or the results thereof are not known definitively, by March 31, 2027, this market will resolve to “No”.
This market will resolve based on a consensus of credible reporting. If there is ambiguity, this market will resolve solely based on official information from the State of California, including the California Secretary of State (https://www.sos.ca.gov/).
This market will resolve to “Yes” if the specified ballot measure is approved by a majority of voters at the California statewide general election currently scheduled for November 3, 2026. Otherwise, this market will resolve to “No.”
If voting on the specified ballot measure does not occur, or the results thereof are not known definitively, by March 31, 2027, this market will resolve to “No”.
This market will resolve based on a consensus of credible reporting. If there is ambiguity, this market will resolve solely based on official information from the State of California, including the California Secretary of State (https://www.sos.ca.gov/).
ปริมาณการซื้อขาย
$2,851วันสิ้นสุด
Nov 3, 2026ตลาดเปิดเมื่อ
Jul 1, 2026, 6:33 PM ETResolver
0x65070BE91...California Proposition 38, set for the November 2026 ballot, would authorize $8.4 billion in general obligation bonds for immunology and immunotherapy research, with half directed to a designated University of California-affiliated institute and the balance awarded via competitive grants, at least $4.2 billion of which must target cancer, heart disease, and Alzheimer’s. Trader sentiment favoring rejection at 55% reflects concerns over the measure’s eligibility criteria, which critics note appear structured to channel substantial funds to one specific nonprofit backed by its billionaire co-founder, alongside broader worries about long-term General Fund repayment obligations and fragmented state research priorities. Recent analyses from the Legislative Analyst’s Office and opinion pieces have highlighted these design elements and debt implications, contributing to the current market positioning ahead of the vote.
สรุปจาก AI ทดลองที่อ้างอิงข้อมูลจาก Polymarket ไม่ใช่คำแนะนำในการเทรดและไม่มีผลต่อการตัดสินตลาดนี้ · อัปเดตแล้ว
ระวังลิงก์ภายนอก
ระวังลิงก์ภายนอก
คำถามที่พบบ่อย